{"id":"NCT03332771","sponsor":"Lexicon Pharmaceuticals","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy","officialTitle":"A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Placebo Added to Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-01","primaryCompletion":"2019-08-06","completion":"2019-09-06","firstPosted":"2017-11-06","resultsPosted":"2021-05-11","lastUpdate":"2021-05-11"},"enrollment":954,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sotagliflozin (SAR439954)","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL"},{"label":"Sotagliflozin 200 mg","type":"EXPERIMENTAL"},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate glycemic control with metformin.\n\nSecondary Objectives:\n\nTo demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in body weight, systolic blood pressure (SBP) in participants with baseline SBP ≥130 millimeter of mercury (mmHg), SBP in all participants, and proportion of participants with at least 1 documented symptomatic hypoglycemic event (≤70 milligrams per deciliter \\[mg/dL\\]).\n\n* To demonstrate the superiority of Sotagliflozin 400 mg compared to placebo on change in HbA1c, body weight, SBP in participants with baseline SBP ≥130 mmHg, SBP in all participants.\n* To demonstrate the superiority of Sotagliflozin 200 mg compared to placebo on change in HbA1c.\n* To demonstrate the non-inferiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c.\n* To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c.\n* To evaluate the safety and tolerability of Sotagliflozin compared to Glimepiride and placebo.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c at Week 52","timeFrame":"Baseline, Week 52","effectByArm":[{"arm":"Placebo","deltaMin":-0.4,"sd":0.187},{"arm":"Sotagliflozin 400 mg","deltaMin":-0.65,"sd":0.101},{"arm":"Sotagliflozin 200 mg","deltaMin":-0.49,"sd":0.114},{"arm":"Glimepiride","deltaMin":-0.61,"sd":0.093}],"pValues":[{"comp":"OG001 vs OG003","p":"0.3306"},{"comp":"OG002 vs OG003","p":"0.7112"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":25},"locations":{"siteCount":142,"countries":["United States","Bulgaria","Hungary","Slovakia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":159},"commonTop":["Headache","Diarrhoea","Vulvovaginal mycotic infection","Hyperglycaemia"]}}